Curaleaf increased its unsolicited bid for Aurora Cannabis by 25%. Beyond the headline price, the transaction offers a revealing look at cannabis M&A, stock consideration, valuation, negotiating leverage and industry consolidation.

DEA’s final rescheduling brief argues marijuana can no longer remain in Schedule I. What could Schedule III mean for cannabis M&A, valuations, cash flow, distressed assets and strategic buyers?